Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of “Moderate Buy” by Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received an average recommendation of “Moderate Buy” from the eighteen analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $72.2941.

Several equities research analysts recently commented on RARE shares. Jefferies Financial Group lowered their price target on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, December 30th. Leerink Partners decreased their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. TD Cowen dropped their price target on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Bank of America reduced their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Finally, Barclays decreased their price objective on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th.

Ultragenyx Pharmaceutical Trading Down 4.3%

NASDAQ RARE opened at $22.49 on Monday. Ultragenyx Pharmaceutical has a 1-year low of $18.41 and a 1-year high of $46.50. The company has a market capitalization of $2.17 billion, a PE ratio of -3.79 and a beta of 0.15. The firm’s fifty day simple moving average is $30.82 and its 200-day simple moving average is $30.74.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The firm had revenue of $159.93 million for the quarter, compared to analyst estimates of $167.42 million. During the same period in the previous year, the business posted ($1.40) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 14.6% on a year-over-year basis. As a group, analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 3,081 shares of the firm’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total value of $112,086.78. Following the transaction, the chief financial officer directly owned 95,146 shares of the company’s stock, valued at approximately $3,461,411.48. This trade represents a 3.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 669 shares during the last quarter. Assetmark Inc. raised its holdings in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the period. Huntington National Bank lifted its position in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the last quarter. Danske Bank A S acquired a new position in Ultragenyx Pharmaceutical during the 3rd quarter worth $39,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in Ultragenyx Pharmaceutical during the second quarter valued at about $55,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.